Humanwell Healthcare (600079.SH) Receives Clinical Trial Approval for HW252001 Tablets

Stock News12-19

Humanwell Healthcare (Group) Co., Ltd. (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" for HW252001 tablets from the National Medical Products Administration. The approval permits clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).

HW252001 tablets, an oral small-molecule investigational drug, are intended for IPF therapy. To date, the cumulative R&D investment for this project amounts to approximately RMB 20 million.

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown cause, characterized by histopathological/imaging features, progressive decline in lung function, acute exacerbations, respiratory failure, and poor prognosis. Current IPF treatments primarily involve anti-fibrotic drugs to slow lung function deterioration and disease progression, with no curative therapies available.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194037590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 15:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194037590","market":"other","top_or_hot":-1,"title":"Humanwell Healthcare (600079.SH) Receives Clinical Trial Approval for HW252001 Tablets","media":"Stock News","content":"<p>Humanwell Healthcare (Group) Co., Ltd. (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the \"Drug Clinical Trial Approval Notice\" for HW252001 tablets from the National Medical Products Administration. The approval permits clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).</p>\n<p>HW252001 tablets, an oral small-molecule investigational drug, are intended for IPF therapy. To date, the cumulative R&D investment for this project amounts to approximately RMB 20 million.</p>\n<p>Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown cause, characterized by histopathological/imaging features, progressive decline in lung function, acute exacerbations, respiratory failure, and poor prognosis. Current IPF treatments primarily involve anti-fibrotic drugs to slow lung function deterioration and disease progression, with no curative therapies available.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humanwell Healthcare (600079.SH) Receives Clinical Trial Approval for HW252001 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumanwell Healthcare (600079.SH) Receives Clinical Trial Approval for HW252001 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-19 15:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Humanwell Healthcare (Group) Co., Ltd. (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the \"Drug Clinical Trial Approval Notice\" for HW252001 tablets from the National Medical Products Administration. The approval permits clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).</p>\n<p>HW252001 tablets, an oral small-molecule investigational drug, are intended for IPF therapy. To date, the cumulative R&D investment for this project amounts to approximately RMB 20 million.</p>\n<p>Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown cause, characterized by histopathological/imaging features, progressive decline in lung function, acute exacerbations, respiratory failure, and poor prognosis. Current IPF treatments primarily involve anti-fibrotic drugs to slow lung function deterioration and disease progression, with no curative therapies available.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1194037590","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194037590","pubTimestamp":1766130626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Humanwell Healthcare (Group) Co., Ltd. (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the \"Drug Clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600079":"ST人福","BK0028":"国家队","BK0239":"医药制造","BK0185":"二线龙头","BK0188":"融资融券","BK0096":"民营医院","BK0070":"员工持股","BK0012":"证金概念"},"translate_title":"人福医疗（600079.SH）HW252001片获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1},"content_text":"Humanwell Healthcare (Group) Co., Ltd. (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd., recently received the \"Drug Clinical Trial Approval Notice\" for HW252001 tablets from the National Medical Products Administration. The approval permits clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).\nHW252001 tablets, an oral small-molecule investigational drug, are intended for IPF therapy. To date, the cumulative R&D investment for this project amounts to approximately RMB 20 million.\nIdiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown cause, characterized by histopathological/imaging features, progressive decline in lung function, acute exacerbations, respiratory failure, and poor prognosis. Current IPF treatments primarily involve anti-fibrotic drugs to slow lung function deterioration and disease progression, with no curative therapies available.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194037590","isCrawlerRequest":true}